Sun Pharma Advanced Research Co Intrinsic Value
Sun Pharma Advanced Research Co (SPARC) median intrinsic value is ₹664.05 from 7 valuation models (range ₹66–₹664), vs current price ₹221.35 — +200.0% upside (Trading Below Calculated Value), margin of safety 66.7%. Browse Sun Pharma Advanced Research C annual reports for revenue, profit, balance sheet and cash flow data.
SPARC Valuation Methods Summary — DCF, Graham Number & P/E
Sun Pharma Advanced Research Co intrinsic value across 7 models vs current price ₹221.35 — upside/downside and value range per method. For current market price and key ratios, visit SPARC screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹664.05 | ₹531.24 - ₹796.86 | +200.0% | EPS: ₹217.08, Sector P/E: 22x |
| Book Value Method | asset | ₹553.38 | ₹498.04 - ₹608.72 | +150.0% | Book Value/Share: ₹405.76, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹66.41 | ₹59.77 - ₹73.05 | -70.0% | Revenue/Share: ₹18.18, P/S: 2.0x |
| PEG Ratio Method | growth | ₹664.05 | ₹597.64 - ₹730.46 | +200.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹664.05 | ₹597.64 - ₹730.46 | +200.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹442.70 | ₹398.43 - ₹486.97 | +100.0% | ROE: 526.1%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹664.05 | ₹597.64 - ₹730.46 | +200.0% | EPS: ₹217.08, BVPS: ₹405.76 |
SPARC Intrinsic Value vs Market Price — All Valuation Models
Sun Pharma Advanced Research Co fair value range ₹66–₹664 vs current market price ₹221.35 across 7 valuation models. Also explore Sun Pharma Advanced Research C share price performance to track price trends across different timeframes.
SPARC Intrinsic Value Analysis — Undervalued or Overvalued?
Sun Pharma Advanced Research Co median intrinsic value ₹664.05, current price ₹221.35 — Trading Below Calculated Value by 200.0%, margin of safety 66.7%.
What is the intrinsic value of SPARC?
Based on our comprehensive analysis using 7 different valuation methods, the estimated intrinsic value of Sun Pharma Advanced Research Co (SPARC) is ₹664.05 (median value). With the current market price of ₹221.35, this represents a +200.0% variance from our estimated fair value.
The valuation range spans from ₹66.41 to ₹664.05, indicating ₹66.41 - ₹664.05.
Is SPARC undervalued or overvalued?
Based on our multi-method analysis, Sun Pharma Advanced Research Co (SPARC) appears to be trading below calculated value by approximately 200.0%.
SPARC Financial Health — Key Ratios vs Industry Benchmarks
Sun Pharma Advanced Research Co financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 23.87 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 526.1% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | -506.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.03x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
SPARC Cash Flow Quality — Operating & Free Cash Flow
Sun Pharma Advanced Research Co operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-360 Cr | ₹-360 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-429 Cr | ₹-429 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-69 Cr | ₹-343 Cr | Negative Cash Flow | 3/10 |